FUS — Fused in Sarcoma

FUS — Fused in Sarcoma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FUS — Fused in Sarcoma</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>FUS</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Fused in Sarcoma</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/2521" target="_blank">2521</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089280" target="_blank">ENSG00000089280</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/137070" target="_blank">137070</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P35637" target="_blank">P35637</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[ALS](/diseases/als), [Frontotemporal Dementia](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Motor cortex, Spinal cord, Nucleus (widespread)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">R521C, R521G, R521H, P525L, H517Q, G507D, R514G, R516G</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color

FUS — Fused in Sarcoma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FUS — Fused in Sarcoma</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>FUS</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Fused in Sarcoma</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/2521" target="_blank">2521</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089280" target="_blank">ENSG00000089280</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/137070" target="_blank">137070</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P35637" target="_blank">P35637</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[ALS](/diseases/als), [Frontotemporal Dementia](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Motor cortex, Spinal cord, Nucleus (widespread)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">R521C, R521G, R521H, P525L, H517Q, G507D, R514G, R516G</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">719 edges</a></td>
</tr>
</table>

FUS — Fused in Sarcoma

Introduction

Fus — Fused In Sarcoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

FUS (Fused in Sarcoma) is a gene located on chromosome 16p11.2 that encodes an RNA-binding protein involved in multiple aspects of RNA metabolism, including transcription, splicing, transport, and translation. FUS is highly expressed in neuronal tissues and plays critical roles in neuronal development, function, and survival. Mutations in FUS are causally linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing a key intersection between these two neurodegenerative disorders [1][2].

The FUS protein belongs to the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins, which are characterized by their involvement in chromosomal translocations that generate oncogenic fusion proteins in various cancers. However, the focus of this page is on FUS's normal physiological functions and its pathogenic role in neurodegeneration.

Protein Structure and Domains

The FUS protein (526 amino acids, ~59 kDa) contains several distinct structural domains that mediate its diverse functions:

Biological Functions

RNA Processing

FUS is a multifunctional RNA-binding protein involved in:

• Transcription regulation: FUS interacts with RNA polymerase II and various transcription factors to regulate gene expression [8].
• Alternative splicing: FUS participates in the splicing machinery, influencing the inclusion or exclusion of specific exons in target mRNAs [9].
• RNA transport: In neurons, FUS localizes to dendritic and synaptic compartments, where it participates in RNA transport and local translation [10].
• mRNA stability: FUS helps stabilize certain mRNA transcripts and regulates their degradation [11].

DNA Damage Response

FUS plays a role in the cellular response to DNA damage:

• FUS is recruited to sites of DNA double-strand breaks
• It interacts with proteins involved in homologous recombination and non-homologous end joining
• Loss of FUS function may contribute to genomic instability in neurons [12]

Neuronal Development

During development, FUS is essential for:

• Neuronal differentiation and maturation
• Synapse formation and function
• Axonal growth and guidance

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Mutations in FUS account for approximately 5-10% of familial ALS cases and rare cases of sporadic ALS [13]. The majority of disease-causing mutations cluster in the C-terminal nuclear localization signal (NLS) region, which impairs FUS nuclear import. Pathological hallmarks include:

• Cytoplasmic FUS aggregates: ALS-associated mutations cause FUS to accumulate in the cytoplasm, where it forms insoluble aggregates [14].
• Nuclear depletion: Impaired nuclear import leads to loss of nuclear FUS function.
• RNA metabolism dysregulation: Altered splicing and transport of critical neuronal mRNAs.
• Stress granule formation: FUS is incorporated into stress granules under cellular stress conditions [15].

Frontotemporal Dementia (FTD)

FUS pathology is also observed in certain subtypes of FTD, particularly in cases with motor neuron disease-like features:

• FUS-positive inclusions are found in neurons and glia
• The distribution of FUS pathology correlates with clinical symptoms
• Some FTD cases show overlap with ALS pathology [16]

Mechanisms of Neurotoxicity

Several mechanisms have been proposed to explain how FUS mutations lead to neurodegeneration:

Therapeutic Approaches

Gene Therapy Strategies

• Antisense oligonucleotides (ASOs): ASOs targeting mutant FUS mRNA are in development to reduce toxic FUS protein levels [18].
• CRISPR-based approaches: Gene editing to correct disease-causing mutations is being explored.
• AAV delivery: Viral vectors can deliver therapeutic genes or ASOs to the central nervous system.

Small Molecule Approaches

• Kinase inhibitors: Compounds targeting kinases involved in FUS phosphorylation may reduce aggregation.
• Aggregation inhibitors: Small molecules that prevent FUS aggregation are under investigation.
• RNA stabilizers: Compounds that restore normal RNA processing are being developed.

Symptomatic Treatments

• Riluzole and edaravone provide modest benefits in ALS
• Multidisciplinary care including ventilatory support, physical therapy, and nutritional support
• Management of FTD symptoms with behavioral and pharmacological interventions

Animal Models

Multiple animal models have been developed to study FUS-related neurodegeneration:

• Transgenic mice: Expressing human FUS mutations recapitulate key aspects of ALS/FTD
• Zebrafish models: Allow rapid screening of FUS mutations and therapeutic compounds
• Induced pluripotent stem cells (iPSCs): Patient-derived neurons provide human disease models [19]

See Also

• [ALS](/diseases/als) — Amyotrophic Lateral Sclerosis
• [TDP-43 Protein](/proteins/tdp-43-protein) — Related RNA-binding protein in ALS/FTD
• [RNA Binding Proteins in Neurodegeneration](/mechanisms/rna-metabolism) — FUS in the context of RNA metabolism dysregulation
• [Stress Granule Homeostasis](/mechanisms/stress-granule-homeostasis-als-ftd) — FUS incorporation into stress granules
• [Spliceosome Dysfunction](/mechanisms/spliceosome) — FUS role in alternative splicing

Relationship to Alzheimer's and Parkinson's Disease

While FUS is primarily associated with ALS and FTD, emerging research suggests potential indirect connections to Alzheimer's disease (AD) and Parkinson's disease (PD) through shared pathological mechanisms:

Alzheimer's Disease Connection

• RNA metabolism dysfunction: Both AD and FUS-related disorders involve dysregulated RNA processing. Proteins like [TDP-43](/proteins/tdp-43-protein) show involvement in AD brain tissue, similar to FUS pathology.
• Stress granule formation: FUS incorporation into stress granules is a feature shared with other neurodegenerative diseases, including AD. Persistent stress granules may contribute to proteostasis failure in AD.
• DNA damage response: FUS plays a role in DNA repair, and impaired DNA damage response is a feature of both FUS-ALS and AD neurons.
• Tau protein interaction: Studies suggest FUS may interact with tau protein pathology, potentially influencing neurofibrillary tangle formation in AD.

Parkinson's Disease Connection

• Alpha-synuclein pathology: While FUS does not directly aggregate in typical PD, both FUS mutations and alpha-synucleinopathies involve stress granule dynamics and RNA dysregulation.
• Mitochondrial dysfunction: FUS mutations impair mitochondrial function, a core pathological feature in PD.
• Excitotoxicity mechanisms: Shared mechanisms of excitotoxic vulnerability may link FUS-related neurodegeneration with PD.
• Dopaminergic neuron vulnerability: Research on FUS in motor neurons may inform understanding of selective vulnerability in PD.

Therapeutic Implications

Understanding these connections may lead to shared therapeutic strategies:

• RNA-targeted therapies: ASOs and RNA modulators developed for FUS-ALS may benefit AD/PD
• Stress granule modulators: Compounds targeting stress granule dynamics could have broad applicability
• Mitochondrial protectors: Shared mitochondrial protective strategies may benefit multiple neurodegenerative conditions

The study of Fus — Fused In Sarcoma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Expression data for FUS](https://human.brain-map.org/microarray/search/show?search_term=FUS)
• Allen Cell Type Atlas: [Cell type expression data](https://celltype.brain-map.org/)
• BrainSpan Atlas: [Developmental transcriptome data](https://www.brainspan.org/)

Pathway Diagram

Disease Mechanism Summary

| FUS Variant | Location | Pathogenesis | Onset |
|-------------|----------|--------------|-------|
| R521C | RRM | Aggregation | Adult |
| R522G | RRM | Nuclear import defect | Adult |
| P525L | NLS | Severe misfolding | Juvenile |
| G156E | RGG2 | Aggregation | Adult |

Recent Research (2024-2025)

Recent advances in FUS-linked ALS research have revealed new mechanisms and therapeutic approaches:

• FUS Mutations in ALS: Comprehensive review of ALS caused by FUS mutations with broad clinical implications[@amyotrophic2025].
• Neuromuscular Denervation: The CCL2-CCR2 axis drives neuromuscular denervation in ALS[@cclccr2025].
• Therapeutic Approaches: Carboplatin restores neuronal toxicity in FUS-linked ALS[@carboplatin2025].
• Drug Delivery: Lipid nanoparticles and transcranial focused ultrasound enhance ASO delivery for ALS therapy[@lipid2025].
• DNA Damage Response: DNA damage response defects induced by TDP-43 and mutant FUS inclusions[@dna2025].
• Extracellular FUS: Release of FUS into extracellular space regulated by its prion-like domain[@release2025].

External Links

• [NCBI Gene: FUS](https://www.ncbi.nlm.nih.gov/gene/2521)
• [UniProt: P35637](https://www.uniprot.org/uniprot/P35637)
• [OMIM: 137070](https://omim.org/entry/137070)
• [Ensembl: ENSG00000089280](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089280)
• [ALS Association](https://www.als.org)
• [ALS Therapy Development Institute](https://www.als.net)

Pathogenic Mutations Comparison

| Mutation | Location | Protein Domain | Disease Association | Pathogenic Mechanism |
|----------|----------|---------------|---------------------|---------------------|
| R521C | Exon 15 | RRM | ALS, FTD | Reduced nuclear import |
| R521G | Exon 15 | RRM | ALS | Impaired RNA binding |
| R522G | Exon 15 | RRM | ALS | Nuclear localization defect |
| P525L | Exon 15 | RRM | Early-onset ALS | Severe nuclear import defect |
| R514G | Exon 14 | RGG2 | ALS, FTD | Altered phase separation |
| G156E | Exon 6 | N-terminal | ALS | Enhanced aggregation |

FUS Protein Domains and Functions

| Domain | Amino Acids | Function | Disease Relevance |
|--------|-------------|----------|-------------------|
| N-terminal Low-complexity | 1-239 | Phase separation, stress granules | Mutations increase aggregation |
| RRM | 285-371 | RNA binding | Mutations reduce binding |
| RGG1 | 372-413 | RNA binding | Mutations affect splicing |
| RGG2 | 421-453 | RNA binding | Altered stress response |
| RGG3 | 460-501 | Protein interactions | FTD mutations affect interactions |
| Zinc Finger | 506-523 | DNA/RNA binding | Mutations disrupt binding |
| NLS | 526-526 | Nuclear localization | Mutations cause cytoplasmic accumulation |

References

Pathway Diagram

The following diagram shows the key molecular relationships involving FUS — Fused in Sarcoma discovered through SciDEX knowledge graph analysis:

Associated Diseases

• Als — associated with

• ALS — associated with

• Alzheimer — associated with

• Alzheimer's disease — associated with

• amyotrophic lateral sclerosis — implicated in

• Amyotrophic Lateral Sclerosis — associated with

• dementia — associated with

• Dementia — associated with

• DEMENTIA — associated with

• frontotemporal — associated with

• frontotemporal dementia — associated with

• Frontotemporal Dementia — associated with

• FRONTOTEMPORAL DEMENTIA — associated with

• frontotemporal lobar degeneration — associated with

• Parkinson — associated with

• Parkinson's disease — associated with

• PARKINSON'S DISEASE — associated with